Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06580210

Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction

The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert. The study will evaluate the results of the spray on the acute rhinitis with nasal obstruction over a 7 days period.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Rhinitis Airway Obstruction Allergic Rhinitis Common Cold Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Infections Nasal Obstruction Nasopharyngeal Diseases Nasopharyngitis Nose Diseases Otorhinolaryngologic Diseases Paranasal Sinus Diseases Pharyngeal Diseases Pharyngitis Picornaviridae Infections RNA Virus Infections Respiration Disorders Respiratory Hypersensitivity Respiratory Insufficiency Respiratory Tract Diseases Respiratory Tract Infections Rhinitis Rhinitis, Allergic Rhinopharyngitis Rhinosinusitis Sinusitis Stomatognathic Diseases Virus Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Pharmacie du Pont Saint Jean, Bayeux, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Patient ≥ 12 years,
  • 2. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhynopharyngitis (cold), rhinosinusitis, or during non-infectious episodes as allergic rhinitis,
  • 3. a. Informed adult patient who has given written consent prior to any study specific procedure,
  • b. Informed minor patients who has given assent and whose legal guardians have given written consent prior to any study specific procedure,
  • 4. Patient able to meet the study requirements (questionnaire completion),
  • 5. Patient affiliated to a social security scheme.

Exclusion criteria

  • 1. Patient who does not want to participate to the clinical investigation,
  • 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray,
  • 3. A child with a history of febrile convulsions,
  • 4. Diseases leading to respiratory insufficiency,
  • 5. Patient suffering from nasal deformity or nasal polyps leading to chronic nasal obstruction,
  • 6. Patient on local ans systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory (NSAIDs), antibiotics and local antiseptics,
  • 7. Concomitant use of other nasal sprays, essential oils for local nasal use and nsal cream or gel,
  • 8. Patient under guardianship, curatorship of safeguard of justice.

Treatment and study plan

Primary outcomes

  1. Performance of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert at 3 days

    Time frame: From Day 0 to Day 3

    Proportion of patients presenting a change of the symptom -nasal obstruction- by at least 1 pt, in the SNOT22 Test (item 22), between Day 0 (at inclusion in the pharmacy before using the spray) and Day 3 (in the evening after the last daily use of the spray). This item is scaled form 0 to 5 and 5 is the worst value.

Secondary outcomes

  1. Performance of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert after the first use

    Time frame: At Day 0

    Proportion of patients who experienced an amelioration of their nasal obstruction after the first use of the spray at Day 0 on patient questionnaire.

  2. Subjective feeling of reduced nasal obstruction on each day of use

    Time frame: From Day 0 and Day 6

    Proportion of patients with a reduction in the symptom -nasal obstruction- of at least 1pt, in the SNOT22 Test (item 22), on each day of use (between Day 0 and Day 6). The item is scaled form 0 to 5 and 5 is the worst value.

  3. Subjective feeling of nasal secretion thinning on each day of use

    Time frame: From Day 0 to Day 6

    Proportion of patients presenting a change of the symptom -thick nasal discharge- by at least 1 pt, in the SNOT22 Test, and on each day of use (from Day 0 to Day 6)

  4. Subjective feeling of nasal cavity cleansing (freshness) on each day of use

    Time frame: From Day 0 to Day 6

    Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6).

  5. Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use

    Time frame: From Day 0 to Day 6

    Proportion of patients who experienced relief of nasal irritation (mucous membrane), on Patient Questionnaire, on each day of use (from Day 0 to Day 6).

  6. Subjective feeling of relief of nasal itching on each day of use

    Time frame: From Day 0 to Day 6

    Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, on each day of use (from Day 0 to Day 6).

  7. Subjective feeling of nasal cavity cleansing (freshness) immediately (2 minuts) after the use of the spray at Day 0

    Time frame: At Day 0 and Day 6

    Proportion of patient who experienced nasal cavity cleansing (feeling of freshness) immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 0 and Day 6.

  8. Subjective feeling of reduced nasal obstruction immediately (2 minuts) after the use of the spray at Day 6

    Time frame: At Day 6

    Proportion of patient who experienced a reduction of nasal obstruction immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 6.

  9. Subjective feeling of reduced nasal obstruction immediately (2 minuts) after the use of the spray at Day 0

    Time frame: At Day 0

    Proportion of patient who experienced a reduction of nasal obstruction immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 0.

  10. Improvement in the patient s quality of life after 7 days of use

    Time frame: At Day 0 et Day 6

    Proportion of patients who experienced an improvement in quality of life, on Patient Questionnaire (scale of 0-10 with 10 is the best value), between Day 0 and Day 6.

  11. Patient satisfaction with the spray after 7 days of use

    Time frame: At Day 6

    Proportion of patients satisfied with the spray on a 4-points scale, at Day 6. The best value is -very satisfied- and the worst value is -very unsatisfied-.

  12. Patient s recommendation of the spray after 7 days of use

    Time frame: At Day 6

    Proportion of patients who would recommend the spray, on a 4-points scale, at Day 6. The best value is -definitely yes- and the worst value is -definitely no-.

  13. Patient s willingness to continue using the spray at Day 6

    Time frame: At day 6

    Proportion of patients who will continue to use the spray and the reason if he does not want to continue, on a 4-points scale, at Day 6. The best value is -definitely yes- and the worst value is -definitely no-.

  14. Facility of use of the spray after 7 days of use

    Time frame: At Day 6

    Proportion of patients who find the spray easy to use, on a 4-points scale, at Day 6. The best value is -very easy- and the worst value is -very difficult-.

  15. Evolution of the overall severity of symptoms

    Time frame: At Day 0 and Day 3

    Average SNOT22 score each day and comparison of SNOT22 score at Day 3 versus DAy 0 (baseline). [0 to 220] with 0 is the best value and 220 is the worst value.

  16. Sensations of tingling and transient irritation

    Time frame: From Day 0 to Day 6

    Proportion of patients with at least 1 adverse event among :

    • tingling sensation
    • sensations of transient irritation during the 7 days of use.

  17. All device deficiencies reported by patients using the spray during the 7 days of use

    Time frame: From Day 0 to Day 6

    Proportion of patients with at least 1 device deficiency during the clinical investigation.

  18. All adverse events reported by patients using the spray during the 7 days of use

    Time frame: From Day 0 to Day 6

    All adverse events reported by the patient during the clinical investigation.

Study contacts

Contact information is provided by the study sponsor or research team.

Léa RADDAY

CONTACT

[email protected]

+33 (0)2 31 47 16 61

Sponsors and collaborators

Lead sponsor

Laboratoires Gilbert

Industry

Collaborators

  • EVAMED

Registry information

Official study title

Prospective Multicenter Clinical Investigation to Evaluate the Performance and the Safety of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert (DEMECA)

Acronym: DEMECA

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Aug 30, 2024
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.